International Stem Cell Corp (ISCO)

OTC Markets
0.270
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.270 - 0.270

ISCO Overview

Prev. Close
0.218
Day's Range
0.27-0.27
Revenue
7.59M
Open
0.27
52 wk Range
0.11-0.54
EPS
-0.088
Volume
0
Market Cap
2.16M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,599
P/E Ratio
-2.40
Beta
0.627
1-Year Change
-42.55%
Shares Outstanding
8,004,389
Next Earnings Date
-
What is your sentiment on International Stem Cell?
or
Market is currently closed. Voting is open during market hours.

International Stem Cell Corp News

  • International Stem Cell reports Q3 results
    • BySeeking Alpha-

    International Stem Cell (OTCQB:ISCO): Q3 EPS of -$0.54Revenue of $1.85M (-4.6% Y/Y)Press ReleaseNow read: MyoKardia (MYOK) Presents At Stifel 2017 Healthcare Conference -...

  • International Stem Cell reports Q2 results
    • BySeeking Alpha-

    International Stem Cell (OTCQB:ISCO): Q2 EPS of -$0.25Revenue of $1.76M (-8.3% Y/Y)Press ReleaseNow read: KemPharm (KMPH) Presents At Canaccord Genuity 37th Annual Growth...

International Stem Cell Corp Analysis

International Stem Cell Corp Company Profile

International Stem Cell Corp Company Profile

Employees
28

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell
  • Long 10K shares from .39.  Good luck all either way, long or short.
    0